PMCTPharmaCountry
    Startseite
Regulatorische Updates30. Aug. 2026•1 Min. Lesezeit

Claudin18.2‑Targeted CAR‑T Therapy Achieves First Global Approval for Solid Tumor

Vom PharmaCountry-Team

Claudin18.2‑targeted CAR‑T therapy is the first CAR‑T to receive global approval for a solid tumor.

A CAR‑T therapy targeting Claudin18.2 has secured global regulatory approval. It is the first CAR‑T approved for a solid tumor.

Zusammengestellt vom PharmaCountry-Team · Quelle: FiercePharma

Themen:#CAR-T#solid tumor#Claudin18.2#gastric cancer#Regulatory Approval

Weitere Artikel

Alle Einblicke anzeigen
Studien & Berichte
Global Finished Dosage Manufacturing Landscape 2026
5. Okt. 2026
Regulatorische Updates
Korea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28. Sept. 2026
Analyse
Pharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28. Sept. 2026